Alterity Therapeutics (ADR) (ATHE)
Develops ATH434, a clinical candidate for multiple system atrophy and related Parkinsonian disorders.
$4.55
At close0.00 (0.00%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions22 holders · as of Jun 30, 2026 | 2.33% | 394.5K ADS | |
| Insiders4 holders · as of Apr 15, 2026 | 1.00% | 170.1K ADS | |
| Otherremainder | 96.67% | 16.38M ADS |
16.94M ADS (1 ADS = 600 ordinary shares) as of Aug 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Jun 2024 annual report; nothing newer is on file here.
Institutions13F, as of Jun 30, 2026
22 holders · 394.5K shares · 7 new positions · 14 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | 139.3K | 0.82% | 0 | Aug 18, 2026 |
| Morgan Stanley | 63.1K | 0.37% | +4.7K | Aug 13, 2026 |
| Greenleaf Trust | 62.0K | 0.37% | +30.0K | Jul 21, 2026 |
| HB Wealth Management, LLC | 58.5K | 0.35% | 0 | Jul 29, 2026 |
| Citadel Advisors LLC | 37.6K | 0.22% | +17.5K | Aug 14, 2026 |
| HRT Financial LP | 17.3K | 0.10% | +17.3Knew | Aug 14, 2026 |
| BNP Paribas Arbitrage, SNC | 10.2K | 0.06% | +3.4K | Aug 13, 2026 |
| Gamma Investing LLC | 2.3K | 0.01% | +453 | Jul 7, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.